Ozempic Lawsuits: Gastroparesis Stomach Paralysis Injury Claims

Who Qualifies to File an Ozempic Lawsuit:

Our Ozempic lawsuit attorneys are reviewing patient complication claims. Complications patients have named in lawsuits include the following adverse fact patterns.

• Gastroparesis / Stomach Paralysis: A condition in which the stomach cannot move food as it should to the small intestines for excretion. No blockage exists, normal digestion is disrupted and it can be life-threatening in severe instances.
• Persistent Vomiting: Constant vomiting can lead to severe dehydration and esophageal damage.
• Persistent Nausea: Painful nausea can disrupt the quality of life and prevent victims from being able to work or perform day-to-day activities. It can also be a symptom of Bezoars, indicating a solid mass of undigested food has hardened in the stomach, which can be life-threatening.
• Persistent Diarrhea: Constant diarrhea can cause severe dehydration and require hospitalization to treat.

 

The same gastrointestinal complications — gastroparesis, severe vomiting, nausea, and diarrhea — have been linked to other GLP-1 receptor agonist medications, including Wegovy, Rybelsus, Mounjaro, Zepbound, Saxenda, Victoza, and Trulicity.

Ozempic Lawsuit Updates:

The petition to consolidate Ozempic lawsuits into multi-district litigation was filed and confirmed. The gastroparesis claims have been consolidated into GLP-1 MDL 3094, Centralized in Pennsylvania. At the time of this writing, there are 66 pending cases against the drugmakers included in the litigation. The semaglutide medications saw a surge in use when doctors began prescribing them and people began taking them off-label for weight loss. MDL 3094 sits alongside other active drug and medical-device dockets our attorneys are handling, including parallels like the Philips CPAP recall litigation.

The ongoing investigation is looking into the following claims against the manufacturers:

• Defective Product Design
• Defective Product Manufacturing
• Improper Labeling & Failure to Warn Patients for Risk of Severe Gastrointestinal Problems
• Medical Malpractice Committed by Plaintiffs' Doctors who Prescribed the Drug Off-label for Weight Loss are a separate cause of action against different defendants

Personal injury lawsuits for gastroparesis are the latest legal development associated with the GLP-1 receptor agonist drug class, which includes the semaglutide medications Ozempic, Wegovy, and Rybelsus; the tirzepatide medications Mounjaro and Zepbound; the liraglutide medications Saxenda and Victoza; and the dulaglutide medication Trulicity.

If you or a loved one have experienced symptoms and were hospitalized after using one of these drugs, our attorneys are here to help.

Separate Claims Against Prescribing Physicians

If a doctor prescribed Ozempic, Mounjaro, or another GLP-1 receptor agonist off-label for weight loss, you may have a separate medical malpractice claim against that physician — independent of any product-liability claim against the drug manufacturer. Off-label prescribing is legal in the United States, but prescribing physicians still owe patients a duty of care. That duty includes evaluating whether the off-label use is medically appropriate for the individual patient, disclosing known risks (informed consent), and monitoring for adverse effects.

A medical malpractice claim is governed by your state's medical-negligence law, not federal product-liability law. The defendants are different (the doctor, clinic, or telehealth provider — not the manufacturer), the standard is different (the medical standard of care), and the statute of limitations is typically shorter than for product-liability claims. In some cases, both claims can be pursued together. Speak with our attorneys about whether a separate prescribing-physician claim may apply to your situation.

On-Label vs. Off-Label: Why It Matters in Your GLP-1 RA Case

Each GLP-1 receptor agonist is FDA-approved for specific medical conditions. Approval status directly affects how a product-liability claim is framed.

On-label (FDA-approved) uses:

• Type 2 diabetes: Ozempic (semaglutide), Mounjaro (tirzepatide), Rybelsus (oral semaglutide), Trulicity (dulaglutide), Victoza (liraglutide)
• Chronic weight management (with BMI criteria): Wegovy (semaglutide), Zepbound (tirzepatide), Saxenda (liraglutide)

Off-label use means a doctor prescribes a drug for a condition the FDA has not approved it to treat — for example, prescribing Ozempic for weight loss in a patient who does not have type 2 diabetes. Off-label prescribing is legal in the United States, but it raises distinct legal issues.

In product-liability cases, the failure-to-warn theory examines whether the manufacturer adequately warned doctors and patients about known risks, including risks during foreseeable off-label use. Labeling and preemption questions were central to the December 2024 ruling in MDL 3094, and the litigation continues. Your eligibility to file a claim does not depend on whether your prescription was on-label or off-label, but the legal theory and evidence may differ. Our attorneys evaluate both pathways.

NAION (Sudden Vision Loss) Claims: Non-Arteritic Anterior Ischemic Optic Neuropathy

Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) is a sudden, often permanent loss of vision caused by impaired blood flow to the optic nerve. A 2024 JAMA Ophthalmology study from Mass Eye and Ear Infirmary found that patients prescribed semaglutide (the active ingredient in Ozempic, Wegovy, and Rybelsus) had a substantially higher risk of developing NAION compared to patients on other diabetes or weight-loss medications. Tirzepatide (Mounjaro, Zepbound) is being investigated for similar associations.

Symptoms typically appear suddenly and are most often noticed on waking — painless vision loss in one eye that does not improve. There is no treatment to restore lost vision once the optic nerve is damaged.

NAION claims are a distinct injury within the broader GLP-1 RA litigation. If you experienced sudden vision loss after starting Ozempic, Wegovy, Rybelsus, Mounjaro, or Zepbound, contact us to evaluate your potential claim.

Compounded Semaglutide Claims

When the FDA listed Ozempic and Wegovy in "shortage" status in 2022–2024, federal law allowed compounding pharmacies to produce semaglutide-based alternatives. Many telehealth weight-loss platforms relied on these compounded versions. Compounded semaglutide is not made by Novo Nordisk and is produced under different regulatory standards than FDA-approved branded drugs.

Reported issues with compounded semaglutide include unapproved salt forms (sodium or acetate), contamination, dosing errors, mislabeling, and inadequate sterility. The FDA has issued multiple safety alerts about adverse events associated with these products. After semaglutide was removed from the FDA shortage list in early 2025, large-scale compounding became sharply restricted.

If your injury followed use of a compounded — not branded — semaglutide product, the legal theory and defendants differ from MDL 3094. Claims may target the compounding pharmacy, the prescribing telehealth provider, or the platform that arranged the prescription.

Filing Gastroparesis Ozempic Lawsuits

If you took any of the semaglutide drugs mentioned and were diagnosed with gastroparesis from a doctor, you may be eligible to file a personal injury lawsuit seeking compensation. Lawyers are investigating patient claims involving severe gastrointestinal problems and are seeking compensation for the adverse impact suffered.

Potential Compensation for Damages May Include:

• Costs of Medical Bills
• Lost Earnings, Past & Future
• Loss of Quality of Life
• Pain & Suffering

People who were forced to go to the emergency room and suffered severe stomach problems should have been adequately warned of the potential risks. Filing a lawsuit against the manufacturers for the personal injuries suffered provides patients with a possible path to compensation. A successful jury verdict would hold these companies responsible for their alleged failure to warn patients of the potential for severe stomach paralysis and its complications.

Who Qualifies for a Claim

If you feel you have a potential injury claim and would like to join the MDL, consider the following criteria to qualify claimants. Potential claimants who fit the following criteria may be eligible to file a claim:

• Experience gastroparesis (stomach paralysis), intestinal blockage, or persistent vomiting with either an Emergency Room visit or hospitalization due to the above injuries.
• Have used one of the following GLP-1 receptor agonist medications: Ozempic, Wegovy, Rybelsus (semaglutide); Mounjaro, Zepbound (tirzepatide); Saxenda, Victoza (liraglutide); or Trulicity (dulaglutide).
• Are no longer taking the medication

 

Alleged: Ozempic Failed to Warn Patients

Plaintiffs in MDL 3094 allege that Novo Nordisk and Eli Lilly failed to adequately warn patients.

The lawsuit alleges Novo Nordisk and Eli Lilly and Co., manufacturers of the weight loss drugs Ozempic and Mounjaro, failed to provide adequate safety warnings about the risk of severe gastroparesis. Patients who suffered paralyzed stomachs after taking the medications may qualify to file an individual lawsuit of their own to join the mass tort litigation.